TORONTO, May 06, 2021 (GLOBE NEWSWIRE) — Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2) and Fio Corporation (“Fio”), through their joint venture company Fionet Rapid Response Group (“FRR”), report on successful, unprecedented on-site testing at Toronto Pearson International Airport (“Toronto Pearson”).
The Greater Toronto Airports Authority (GTAA), operator of Toronto Pearson, and FRR worked closely to create a first-of-its-kind biosecurity testing capability at the airport, which has produced outstanding results in its first full month of operation.
FRR’s Platform Tested 8,000 People, with an average 30-Minute turnaround
The Fionet Platform (“Fionet”) performed antigen testing for 8,000 people, including airport employees and internationally departing passengers. Airlines flown included: AeroMéxico, Air Canada, Air France, Air India, American, Avianca, British Airways, Caribbean Airlines, Copa Airlines, Cathay Pacific, Delta, El Al, EVA Air, Egyptair, Emirates, Ethiopian Airlines, Etihad, KLM, Korean Air, LOT Polish Airlines, Lufthansa, Philippine Airlines, TAP Air Portugal, Turkish Airlines, United, and WestJet.
Fionet’s innovations include replicable assembly lines that can be parallelized. Five Fionet devices, each doing 60 tests/hour, can clear 300 passengers/hour – e.g., a Boeing 737 or an Airbus A310.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/50f6be7c-6534-4745-b2f3-2e9e3dc77de8
GTAA deployed Fionet Platform for all parts of its biosecurity testing process
GTAA selected Fionet not only for testing, but also for integrating the complex processes of testing, reporting, and passenger logistics.
All modules of Fionet Platform are deployed at Toronto Pearson: (1) Fionet Manager does browser-based registration, scheduling, reporting; (2) Fionet Deki Devices do rapid diagnostic tests (RDT); (3) Fionet Broker…